4//SEC Filing
Versant Affiliates Fund V, L.P. 4
Accession 0001209191-23-043527
CIK 0001764974other
Filed
Jul 26, 8:00 PM ET
Accepted
Jul 27, 4:23 PM ET
Size
77.8 KB
Accession
0001209191-23-043527
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying)
Versant Affiliates Fund V, L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying)
Versant Ventures V (Canada), L.P.
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Versant Ventures V, LLC
10% Owner
Transactions
- Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying)
Versant Venture Capital V, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Versant Vantage II GP, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Transactions
- Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying)
Transactions
- Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Versant Vantage II GP-GP, LLC
10% Owner
Transactions
- Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Versant Vantage II, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2023-07-25+84,313→ 84,313 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+15,028$180,336→ 207,486 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+192,458→ 192,458 total(indirect: By Versant Venture Capital V (Canada) LP) - Conversion
Common Stock
2023-07-25+76,067→ 76,067 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Common Stock
2023-07-25+2,528,864→ 2,528,864 total(indirect: By Versant Venture Capital V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−601,077→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (75,255 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−117,730→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (14,739 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−106,208→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (13,297 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−582,206→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (72,892 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−230,117→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (28,810 underlying) - Conversion
Common Stock
2023-07-25+274,990→ 274,990 total(indirect: By Versant Vantage II, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+197,458$2,369,496→ 2,726,322 total(indirect: By Versant Venture Capital V, L.P.) - Purchase
Common Stock
2023-07-25$12.00/sh+6,575$78,900→ 90,888 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−7,897,999→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (988,832 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−3,530,789→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (442,055 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−7,650,043→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (957,787 underlying) - Conversion
Series B-2 Preferred Stock
2023-07-25−255,081→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (31,936 underlying) - Conversion
Series C Preferred Stock
2023-07-25−1,119,729→ 0 total(indirect: By Versant Venture Capital V, L.P.)→ Common Stock (140,190 underlying) - Conversion
Series C Preferred Stock
2023-07-25−85,217→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (10,669 underlying) - Conversion
Series C Preferred Stock
2023-07-25−37,283→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (4,667 underlying) - Purchase
Common Stock
2023-07-25$12.00/sh+5,939$71,268→ 82,006 total(indirect: By Versant Affiliates Fund V, L.P.) - Conversion
Series A Preferred Stock
2023-07-25−263,349→ 0 total(indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)→ Common Stock (32,971 underlying) - Conversion
Series A Preferred Stock
2023-07-25−237,575→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (29,744 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-25−268,711→ 0 total(indirect: By Versant Venture Capital V (Canada) LP)→ Common Stock (33,642 underlying) - Conversion
Series C Preferred Stock
2023-07-25−33,682→ 0 total(indirect: By Versant Affiliates Fund V, L.P.)→ Common Stock (4,216 underlying) - Conversion
Series D Preferred Stock
2023-07-25−2,196,402→ 0 total(indirect: By Versant Vantage II, L.P.)→ Common Stock (274,990 underlying)
Footnotes (6)
- [F1]Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.
- [F2]Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
- [F3]Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
- [F4]Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
- [F5]Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
- [F6]Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
Turnstone Biologics Corp.
CIK 0001764974
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001589095
Filing Metadata
- Form type
- 4
- Filed
- Jul 26, 8:00 PM ET
- Accepted
- Jul 27, 4:23 PM ET
- Size
- 77.8 KB